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PrognosisObjective. There is great need for better risk stratification in vulvar squamous cell carcinoma (VSCC). Our aim
was to define the prognostic significance of stratifying VSCC based on p16 and p53 immunohistochemistry (IHC)
as surrogate markers for HPV and TP53 mutations.
Methods. A large retrospective cohort of surgically treated women with primary VSCC was used. VSCC were
classified into three subtypes: HPV-positive (HPVpos), HPV-negative/p53 mutant (HPVneg/p53mut), and HPV-
negative/p53wildtype (HPVneg/p53wt). Overall survival (OS), relative survival (RS), and recurrence-free period
(RFP) were depicted using the Kaplan-Meier method and survival curves for relative survival; associations were
studied using univariable and multivariable Cox proportional hazard models.
Results. Of the 413 VSCCs, 75 (18%) were HPVpos, 63 (15%) HPVneg/p53wt, and 275 (66%) HPVneg/p53mut
VSCC. Patients with HPVneg/p53mut VSCC had worse OS and RS (HR 3.43, 95%CI 1.80–6.53, and relative excess
risk (RER) of 4.02; 95%CI 1.48–10.90, respectively, and worse RFP (HR 3.76, 95%CI 2.02–7.00). HPVpos VSCC pa-
tients showed most favorable outcomes. In univariate analysis, the molecular subtype of VSCC was a prognostic
marker for OS, RS and RFP (p=0.003, p=0.009, p< 0.001, respectively) and remained prognostic for RFP even
after adjusting for known risk factors (p = 0.0002).
Conclusions. Stratification of VSCC by p16- and p53-IHC has potential to be used routinely in diagnostic pa-
thology. It results in the identification of three clinically distinct subtypes and may be used to guide treatment
and follow-up, and in stratifying patients in future clinical trials.
© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).gy, Leiden University Medical
).
. This is an open access article under1. Introduction
Clinical management of vulvar cancer raises several challenges for
the oncological gynecologist. With an incidence of 1–2 per 100.000
women and a median age of 70, vulvar cancer is a rare cancer of elderlythe CC BY license (http://creativecommons.org/licenses/by/4.0/).
K.E. Kortekaas, E. Bastiaannet, H.C. van Doorn et al. Gynecologic Oncology 159 (2020) 649–656women, although the disease has shown rising incidence rates with
concurrently decreasingmedian age at onset over the past few decades
[1–3]. The great majority of vulvar cancers are squamous cell carcino-
mas [4].
Vulvar squamous cell carcinoma (VSCC) is a heterogeneous disease
with an overall 5-year survival rate of 70% [4]. Current treatment is
highly dependent on anatomical extent of disease, as represented in
the International Federation of Gynecology and Obstetrics (FIGO)
2009 staging system [5]. Treatment for early-stage VSCC includes
groin surgery in addition to wide local tumor resection according to in-
ternational treatment recommendations [6]. The presence and number
of lymph node metastasis is the main prognostic factor for recurrence
and survival: 5-year disease-specific survival ranges between 70% and
95% in patients with negative inguino-femoral lymph nodes and de-
creases to 25% to 41% if groin nodes are affected [4,7]. In addition to sur-
gery, further treatment modalities such as adjuvant (chemo)
radiotherapy, especially for locally advanced and metastatic disease,
are recommended [6]. Treatment for VSCC often leads to substantial
and long-term morbidity in affected patients due to loss of function of
adjacent vital structures (bladder, anus and/or clitoris), lymphedema,
sexual and psychological dysfunction and wound healing disorders
[8]. Therefore, there must be a careful balance between adequate treat-
ment and morbidity. Due to the rarity of the disease randomized con-
trolled trials in VSCC are lacking; and criteria for different treatment
modalities therefore remain controversial with low levels of evidence.
There is a critical need to improve the identification of high-risk patients
who may benefit from more intensive or novel therapies. On the other
hand, it is necessary to identify patients at low risk for recurrence or
death for whom less aggressive therapy might be safe.
Recent evidence has provided novel insights into themolecular het-
erogeneity of VSCC [9,10]. Two intrinsically different VSCC subtypes
have been identified; one is initiated by a high-risk human papilloma
virus (HPV) infection and accounts for ~20% of VSCC [10]. The more
common VSCC subtype however is HPV-negative and most likely initi-
ated by TP53 mutations [9,11–13]. There is increasing evidence that
HPV-positive VSCC have favorable clinical outcomes compared to
HPV-negative VSCC [9,10,14–18]. Clinical outcomes of HPV-negative
VSCC varywidely and further prognostic stratification by TP53mutation
status has been recently suggested [9,19,20]. HPV-negative VSCC with
wildtype TP53 was poorly defined, since sequencing is not routinely
performed. Assessment of TP53 status by p53 immunohistochemistry
(IHC) is thought to be suboptimal [21]. However, we recently reported
on a pattern-based p53-IHC assessment for VSCC, allowing near-
perfect prediction of TP53 mutational status [19,20] with a high level
of interobserver agreement. This improved approach towards p53-IHC
in VSCC, now allows us to study the potential clinical relevance of strat-
ifying HPV-negative VSCC by TP53 status. In addition to p53-IHC, p16-
IHC is an excellent surrogate marker for HPV-presence [22] which indi-
cates that two IHCs can be used to classify VSCC into three molecular
subtypes.
In this study, we tested the hypothesis that molecular classification
in VSCC is associated with significant differences in prognosis. We
used an easy clinically applicable molecular classification tool based
on p16- and p53-IHC in a large, well-characterized retrospective cohort
of VSCC. This classification may designate patients into less heteroge-
neous and more appropriate risk groups. As a consequence, better pre-
diction for clinical outcome and guidance for personalized treatment
protocols can be envisioned.
2. Material and methods
Institutional approval for this study was obtained from each of the
participating centers. Primary VSCCs treated between January 2000
and December 2015 with clinical follow-up data were collected from
two Dutch university hospitals (Leiden University Medical Center
(LUMC) and ErasmusMC Rotterdam (EMC). All patients were treated650according to the Dutch national guideline (www.oncoline.nl) consisting
of awide local excision or vulvectomy and a sentinel lymph node proce-
dures or inguinofemoral lymphadenectomy. The standard follow-up
schedule was; 6 weeks postoperative, the first two years after initial
treatment every 3 months, in the fourth and fifth year every 6 months
and thereafter once a year. Inclusion criteria were surgical treatment
with curative intent and availability of formalin-fixed paraffin-
embedded (FFPE) blocks from resection specimens. An exclusion crite-
rium was previous (chemo)radiotherapy in the pelvic area.
Clinicopathogical variables were collected from the electronic patient
file. These comprised FIGO 2009 staging, tumor size, depth of invasion,
lymphovascular space involvement (LVSI), number and localization of
involved lymph nodes, treatment characteristics, pathological resection
margins, date and location of recurrent disease, and/or date of last
follow-up or death. Survival data were linked to the Dutch Cancer Reg-
istries till October 2017. All FFPE blocks were cut in 4 μm slides and
stained with hematoxylin and eosin (HE) and were checked for the
presence of invasive VSCC by a pathologist with gynecological expertise
(TB). In case of absence of the tumor, the patient was excluded from the
study.
2.1. P16 immunohistochemistry
We performed p16-IHC (CINtec p16ink4A histology; 1:25 dilution;
clone E6H4) on all cases [9]. Two observers (KEK and TB) scored p16-
IHC. Presence of the integration of high-risk HPV was defined as
“block-type” p16 expression according to consensus recommendations
[23]. Upon block-type p16 expression, we confirmed the presence of
HPVbyHPV-PCR (LiPa genotyping, Innogenetics, Gent, Belgium) includ-
ing the determination of theHPV genotype on FFPEmaterial. This group
was referred to as HPV-positive VSCC (HPVpos VSCC). Absent or patchy
expression of p16was classified as HPV-negative VSCC (HPVneg VSCC).
In case of discordance between HPV-PCR and p16-IHC, cases were ex-
cluded from the study since these tumors might influence the outcome
of the predefined subtypes [24].
2.2. P53 immunohistochemistry
Subsequently, HPVneg VSCC were categorized based on the pattern
of p53-IHC expression. P53-IHC was performed with Dako Ominis
FLEX+ detection system (p53 antibody, clone DO-7, Dako, mouse
monoclonal, ready-to-use) [19], and was assessed by two observers
(KEK and TB). Six different p53-IHC patterns were described, of which
two p53-IHC patterns (scattered and mid-epithelial) were classified as
final class ‘p53-IHCwildtype’ (HPVneg/p53wtVSCC), and the remaining
four patterns (basal, parabasal to diffuse, cytoplasmic, and absent) as
final class ‘p53-IHCmutant’ (HPVneg/p53mut VSCC) [19,20]. The agree-
ment on final class p53-IHC (wildtype versus mutant) using this ap-
proach was substantial (k = 0.71, p < 0.001) and resulted in a
sensitivity of 05% and specificity of 100%. The accuracy of p53-IHC to
predict TP53mutationswas 97% [19]. In addition, tumorswere excluded
when one of the assays failed, because amolecular subtype could not be
assigned to the particular case.
2.3. Statistical analysis
End points of the study were overall survival (OS), relative survival
(RS), and recurrence-free period (RFP). The OS was defined as the
time from the date of primary surgery to date of death of any cause. Be-
cause VSCC mainly affects elderly women [1], it is likely that these pa-
tients could die from non-cancer related causes. Therefore, we
calculated the RS which takes into account the risk of dying from
other causes than VSCC. The RS is based on a ratio of the observed sur-
vival in our cohort and the survival that would have been expected
based on the corresponding general population, matched for age, gen-
der, and year of incidence [25]. The RS is preferred above the disease-
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cation of the cause of death [26]. The RFPwas defined as the time period
from surgery to any recurrence as event or end of follow-up. In order to
exclude cases with potential residual disease, patients with tumor-
positive surgical margins who did not undergo re-excision were ex-
cluded in the RFP analysis.
For data analysis and illustration of the graphs andfigures, the statis-
tical software package SPSS 23.0 (SPSS Inc., Chicago, IL), or STATA/SE
12.0 was used. The baseline characteristics between the groups were
calculated by the chi-square test (categorical data) or Mann-Whitney
U test (numerical data). The RS was calculated by the Ederer II method
[27,28] for which national life tables from www.mortality.org were
used to estimate expected survival. Relative excess risks (RERs) of
death were estimated using an adjusted generalized linear model with
a poisson distribution, based on collapsed relative survival data, using
exact survival times.
We used a univariate analysis to identify prognostic variables for
each clinical outcome, and a Cox proportional Hazards model to deter-
mine independent predictive variables for the corresponding outcome.
The global deviance test was calculated in both uni- and multivariate
analysis for all variables irrespective of individual parameters. Two
sided p-values <0.05 and an alpha of <0.05were considered significant.
3. Results
3.1. Clinicopathological characteristics
A total of 553 patients with primary VSCC were treated at the LUMC
(n = 179) and EMC (n = 374) between January 2000 and December
2015. We excluded 107 patients based on the exclusion criteria
(supplementary file S1). Thirty-three patients were excluded due to
absence of VSCC or failed IHC (n = 4). Three cases were excluded due
to discordancy between p16-IHC and HPV-PCR (Fig. 1, supplementary
file S1). The baseline clinical and histopathological characteristics of
the 413 included patients stratified by molecular subtype are shown
in Table 1. Median follow-up time for the cohort was 30 months
(range 0–201).
The majority of the tumors (275/413, 66%) were HPVneg/p53mut
VSCC, 75/413 (18%) were HPVpos VSCC, and 63/413 (15%) were
HPVneg/p53wt VSCC (Table 1, Fig. 1). HPVposVSCCweremostly caused
by hr-HPV type 16 (71%), followed by type 33 (20%), and type 18 (8%).Fig. 1.Decision tree for molecular vulvar squamous cell carcinoma subtyping using surrogatem
IHC expression as hrHPV-dependent VSCC (HPVpos VSCC), which was subsequently confirme
independent (HPVneg VSCC) tumors. HPVneg VSCC were categorized based on p53-IHC ex
wildtype’ (HPVneg/p53mut VSCC). In case of basal, parabasal to diffuse, absent or cytoplasm
HPVpos VSCC = HPV-positive vulvar carcinoma, HPVneg VSCC = HPV-negative VSCC, HPVn
negative and p53 mutant VSCC, IHC = immunohistochemistry, VSCC = vulvar squamous cell
651Age, FIGO stage, depth of invasion, LVSI, and treatment modality were
all significantly associated with molecular subtype. Age at surgery for
women with HPVpos VSCC (median 59 years) was lower than in the
HPVneg/p53wt VSCC and HPVneg/p53mut VSCC (73 versus 75 years,
respectively). The majority of patients with HPVpos VSCC (59/75, 79%)
or HPVneg/p53wt VSCC (51/63, 81%) tumors presented with stage I/II
disease, compared to 156/275 (57%) HPVneg/p53mut VSCC. The latter
weremore likely to have an advanced stage (III) disease and receive ad-
juvant (chemo)radiotherapy. Eighty-one percent of patients with stage
III disease had HPVneg/p53mut VSCC tumors. HPVpos VSCC and
HPVneg/p53wt VSCC were similar with respect to all measured clinico-
pathological parameters except for age (supplementary file S2).
3.2. Clinical outcomes
HPVneg/p53mut VSCC have worse outcomes than other molecular
subtypes, with HPVpos VSCC representing the group with best overall
and relative survival (Fig. 2). The 5-years overall survival was 83%
(69.9–90.3%), 64% (48.9–75.9%), and 48% (41.5–55.0%) for HPVpos
VSCC, HPVneg/p53wt VSCC, and HPVneg/p53mut VSCC, respectively
(Fig. 2A). A similar patternwas seen for RS,whereHPVposVSCC showed
survival benefit (5-year RS 91.1% (77.1–99.5%)) compared to HPVneg/
p53wt VSCC (77.8% (59.8–91.6%)) and HPVneg/p53mut VSCC (59.7%
(51.2–67.8%), Fig. 2B). Comparison between the different molecular
subtypes, revealed that patients with HPVpos VSCC had better OS at 5-
years than patients with HPVneg/p53wt VSCC (HR 2.16 (1.00–4.64),
p = 0.049) and HPVneg/p53mut VSCC (HR 3.43 (1.80–6.52),
p < 0.001), HPVneg/p53wt VSCC also had 5-years OS benefit over
HPVneg/p53mut VSCC (HR 0.63 (0.39–1.02), p = 0.06). The relative
survival of HPVpos VSCC and HPVneg/p53wt VSCC was comparable
(RER 2.26 (0.69–7.37); p = 0.18), but HPVneg/p53mut VSCC showed
worst RS (RER 4.02 (1.48–10.90); p = 0.006). The relative survival be-
tween HPVneg/p53wt VSCC and HPVneg/p53mut VSCC did not differ
(RER 0.56 (0.28–1.15); p = 0.11). Univariate analysis demonstrated
that molecular subtype was associated with OS (p = 0.003), RS (p =
0.009), and RFP (p < 0.001), as were age, FIGO stage, tumor size,
depth of invasion, and treatment modality (Table 2). LVSI and positive
margins were associated with OS (p < 0.001) and RS (p = 0.001) but
not with RFP (p = 0.36 and p = 0.32, respectively). In multivariable
analyses that included clinicopathological factors associated with out-
come [10], age ≥ 70 years, FIGO stage ≥IIIA, and size >2 cm remainedarkers.We performed p16-IHC on all cases, and categorized tumors with “blocktype” p16-
d by HPV-PCR. VSCC with patchy or absent expression of p16 were referred to as hrHPV-
pression. Both scattered and mid-epithelial p53 expression were classified as ‘p53-IHC
ic p53 expression, tumors were classified as ‘p53-IHC mutant’ (HPVneg/p53mut VSCC).
eg/p53wt VSCC = HPV-negative and p53 wildtype VSCC, HPVneg/p53mut VSCC = HPV-
carcinoma.
Table 1
Association between molecular subtype and clinicopathological variables.
HPVpos VSCC HPVneg/p53wt VSCC HPVneg/p53mut VSCC p-value
(n = 75, 18%) (n = 63, 15%) (n = 275, 66%)
Age – yr (median, range) 59 (19–92) 73 (35–91) 75 (23–98) <0.0001
FIGO 2009 (n, %) <0.0001
IA 9 (12.0%) 3 (4.8%) 2 (0.5%)
IB 50 (66.7%) 46 (73.0%) 143 (52.0%)
II 0 (0.0%) 2 (3.2%) 11 (4.0%)
IIIa 1 (1.3%) 2 (3.2%) 57 (20.7%)
IIIA 13 (17.3%) 6 (9.5%) 13 (4.7%)
IIIB 1 (1.3%) 4 (6.4%) 42 (15.3%)
IIIC 1 (1.3%) 0 (0.0%) 7 (2.6%)
Size in cm (median, range) 19 (1–72) 25 (1.9–120) 25 (2−110) 0.25
≤2 (n, %) 39 (52.0%) 24 (39.1%) 100 (36.4%)
2–4 (n, %) 23 (30.7%) 23 (36.5%) 102 (37.1%)
≥4 (n, %) 11 (14.7%) 15 (23.8) 70 (2.6%)
Missing 2 (2.7%) 1 (1.6%) 3 (1.1%)
Depth of invasion in mm (median, range) 3 (0.4–35) 4.5 (0.5–27) 6 (1–69) 0.001
≤4 (n, %) 46 (61.3%) 29 (46.0%) 95 (34.6%)
>4 (n, %) 29 (38.7%) 34 (54.0%) 179 (64.0%)
Missing 0 (0.0%) 0 (0.0%) 1 (0.4%)
LVSI (n, %) 0.03
No 58 (77.3%) 51 (81.0%) 219 (79.6%)
Yes 7 (9.3%) 6 (9.5%) 44 (16.0%)
Missing 10 (13.3%) 6 (9.5%) 12 (4.4%)
Tumor positive margins (n, %) 0.26
No 70 (93.3%) 59 (93.7%) 243 (88.4%)
Yes 5 (6.7%) 4 (6.4%) 32 (11.6%)
Missing 0 (0.0%) 0 (0.0%) 0 (0.0%)
HPV genotyping
Type 16 53 (70.7%)
Type 18 6 (8.0%)
Type 33 9 (20.0.%)
Other 4 (5.3%)
Treatment modality (n, %) 0.005
Surgery 60 (80.0%) 52 (82.5%) 174 (63.3%)
Surgery & (chemo)radiotherapy 15 (20.0%) 11 (17.5%) 101 (36.7%)
Recurrence (n, %) <0.0001
No 64 (85.3%) 47 (74.6%) 156 (56.7%)
Yesb 11 (14.7%) 16 (25.4%) 119 (43.3%)
Local (first recurrence) 10 (13.3%) 13 (20.6%) 94 (34.2%)
Locoregional (first recurrence) 1 (1.3%) 3 (4.8%) 25 (9.1%)
Distant (first recurrence) N/A N/A N/A
Number of recurrences (n,%) 0.48
1 8 (72.7%) 8 (50.0%) 73 (63.9%)
≥2 3 (27.3%) 8 (50.0%) 46 (38.7%)
Time to first recurrence in months (median, range)c 18 (8–145) 37.5 (8–103) 19 (1–125) 0.14
Survival status (n, %) <0.001
Alive 61 (81.3%) 22 (34.9%) 146 (53.1%)
Dead 14 (18.7%) 41 (65.1%) 129 (46.9%)
HPV= human papilloma virus, LVSI = lymphovascular space invasion.
All significant p-values are shown in bold.
a Not all patients were eligible for lymphadenectomy, therefore the stage of disease was at least FIGO III based on imaging and/or lymph-node puncture.
b Recurrences were scored based on pathology or imaging reports. The depth of invasion, LVSI, perineural growth were scored based on the pathology reports.
c Two patients had a follow-up period of <1 month.
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RS, age (p = 0.02), FIGO stage ≥IIIA (p = 0.001), and size >2 cm (p =
0.04) were independent predictive factors.
Among the 275 HPVneg/p53mut VSCC there were 119 recurrences
(43%) compared to 16/63 (25%) and 11/75 (15%) in the HPVneg/
p53wt VSCC and HPVpos VSCC, respectively (p < 0.0001, Table 1). The
median time to first recurrence did not differ between the subtypes. Re-
currences were local in the great majority of cases (91% for HPVpos
VSCC, 81% for HPVneg/p53wt VSCC, and 79% for HPVneg/p53mut
VSCC). HPVneg/p53wt VSCC and HPVneg/p53mut VSCC more often
had multiple (≥2) recurrences, however this was not significant. The
hazard ratios for RFP for HPVpos VSCC compared to HPVneg/p53wt
VSCC was 1.64 (0.74–3.61, p = 0.22) and compared to HPVneg/
p53mut VSCC 3.76 (2.02–7.00, p < 0.001) (Fig. 2C). Interestingly,652there was no difference between HPVpos VSCC and HPVneg/p53wt
VSCC regarding RFP, whereas HPVneg/p53mut VSCC showed signifi-
cantly worse RFP compared to the other molecular subtypes. In a multi-
variate analysis for RFP, age ≥ 70 years (p = 0.005), and molecular
subtype (p = 0.0002) remained of significant impact irrespective of
other clinicopathological factors. The effect of molecular subtype on
RFP was driven by HPVneg/p53mut VSCC (HR 3.04 (95% CI 1.59–5.81;
p = 0.001, Table 3).
4. Discussion
Clinical management of women with vulvar cancer is highly chal-
lenging for oncological gynecologists, because current treatment is as-
sociated with significant short- and long-term morbidity [29], and
Fig. 2. Significant differences in clinical outcome for the three molecular subtypes of vulvar squamous cell carcinoma. HPVpos VSCC showed best clinical outcome in overall survival (OS,
panel A), relative survival (RS, panel B), and recurrence-free period (RFP, panel C), in contrast to HPVneg/p53mut VSCC which showed worst clinical outcome. HPVneg/p53wt VSCC
showed an intermediate risk for both OS and RS, but shows no difference compared to HPVpos VSCC for RFP. Patients at risk could not be determined for relative survival, due to the
nature of the calculated outcome. HPVpos VSCC = HPV-positive vulvar carcinoma, HPVneg VSCC = HPV-negative VSCC, HPVneg/p53wt VSCC = HPV-negative and p53 wildtype
VSCC, HPVneg/p53mut VSCC = HPV-negative and p53 mutant VSCC, HR = hazard ratio, OS = overall survival, REF = reference, RS = relative survival, RFP = recurrence-free period.
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great need to improve assessment of individual risks for recurrence
and death by for instance the use of clinicopathological and molecular
features of tumors. The question addressed in this study was whether
molecular VSCC subtypes are of prognostic significance. We performed
a molecular classification using the relatively straightforward interpre-
tation of the widely available p16- and p53-IHC. We applied themolec-
ular classification tool to a large cohort of VSCC for which we obtained
detailed clinicopathologic data and outcomes. We were able to define
three molecular subgroups in VSCC; HPVpos VSCC (18%), HPVneg/
p53wt VSCC (15%), and HPVneg/p53mut VSCC (66%). HPVpos VSCC
were associated with early stage disease, and with younger age com-
pared to the HPVneg VSCC subtypes. The three subtypes showed signif-
icant different clinical outcomes for both OS, RS, and RFP with worst
prognosis for HPVneg/p53mut VSCC. Importantly, within the HPVneg
VSCC, tumors with wildtype p53 had similar clinicopathological653parameters as HPVpos VSCC except for age, and showed better overall
survival and a longer RFP compared to HPVneg/p53mut VSCC.
Current treatment decisions for VSCC are based on a clinicopatho-
logic risk stratification strategy with all patients with the same FIGO
stage receiving the same treatment [31]. This staging system is however
not highly predictive of the outcome [5], and this may be due to the het-
erogeneity of VSCC. Our data showed that among VSCCs, women with
tumors classified as HPVneg/p53mut VSCC had the worst outcomes
compared to womenwith HPVneg/p53wt VSCC and HPVpos VSCC, sug-
gesting that intrinsically these tumors have a more aggressive biology.
OS, RS, and RFP were all significantly reduced for the HPVneg/p53mut
VSCC in an univariate analysis. The majority of the recurrences were
local recurrences in all subgroups. The minority of the recurrences in
the HPVpos VSCC group were locoregional recurrences (9%), followed
by 19% for HPVneg/p53wt VSCC, and 21% for HPVneg/p53mut VSCC
(Table 1). Although the sample size is limited, the percentage of
Table 2
Univariate analysis of all vulvar squamous cell carcinoma patients (n = 413).
Overall survival Relative survival Recurrence-free period
Factor HR (95%CI) p-value RER (95%CI) p-value HR (95%CI) p-value
Age (years) <70 1.0 1.0 1.0
≥70 3.33 (2.29–4.85) <0.001 2.43 (1.53–3.85) <0.001 1.83 (1.34–2.67) <0.001
Molecular subtype 0.003a 0.009a <0.001a
HPVpos VSCC 1.0 1.0 1.0
HPVneg/p53wt VSCC 2.16 (1.00–4.64) 0.049 2.26 (0.69–7.37) 0.18 1.64 (0.74–3.61) 0.22
HPVneg/p53mut VSCC 3.43 (1.80–6.52) <0.001 4.02 (1.48–10.90) 0.006 3.76 (2.02–7.00) <0.001
FIGO stageb I/II 1.0 1.0 1.0
III/IIIA/IIIB 2.32 (1.61–3.34) <0.001 3.10 (1.81–5.31) <0.001 1.01 (0.67–1.52) 0.94
IIIC 4.76 (3.14–7.21) <0.001 7.32 (4.21–12.75) <0.001 1.89 (1.14–3.14) 0.01
Size (cm) ≤2 1.0 1.0 1.0
2–4 2.26 (1.47–3.46) <0.001 3.54 (1.61–7.76) 0.002 1.22 (0.84–1.77) 0.30
≥4 4.55 (2.95–7.03) <0.001 8.06 (3.71–17.48) 0.001 1.72 (1.07–2.77) 0.02
Unknown 0.76 (0.10–5.58) 0.79 1.34 (0.11–16.13) 0.82 0.93 (0.23–3.80) 0.92
Depth of invasion (mm)c ≤4 1.0 1.0 1.0
>4 2.36 (1.64–3.41) <0.001 3.37 (1.85–6.15) <0.001 1.65 (1.16–2.33) 0.005
LVSI No 1.0 1.0 1.0
Yes 2.0 (1.37–2.94) <0.001 2.27 (1.39–3.70) 0.001 1.27 (0.48–3.70) 0.36
Unknown 2.5 (1.16–5.56) 0.02 2.70 (0.97–7.69) 0.058 1.79 (0.78–4.17) 0.17
Positive margin No 1.0 1.0 1.0
Yes 2.10 (1.37–3.20) 0.001 2.43 (1.43–4.12) 0.001 1.40 (0.71–2.77) 0.32
Treatment Surgery 1.0 1.0 1.0
Surgery & (chemo)radiotherapy 2.33 (1.70–3.21) <0.001 3.03 (1.95–4.71) <0.001 1.46 (1.02–2.09) 0.036
HPV = human papillomavirus, HPVpos VSCC = HPV-positive vulvar carcinoma, HPVneg VSCC = HPV-negative VSCC, HPVneg/p53wt VSCC = HPV-negative and p53 wildtype VSCC,
HPVneg/p53mut VSCC = HPV-negative and p53 mutant VSCC, HR = hazard ratio, LVSI = lymphovascular space invasion, RER = relative excess risk. Only 29 patients were diagnosed
with locoregional, and were therefore not included in the univariate analysis. Significant p-values are shown in bold.
a Global deviance test without individual parameters.
b We combined the FIGO stages for the analysis into three categories: 1) FIGO stage I and II, 2) III, IIIA, IIIB, and 3) IIIC due to limitations by sample size.
c One patient unknown, excluded from analysis.
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with worse overall survival due to the involvement of the lymph
nodes [7,32]. This could be an explanation for the apparent mismatch
between the prognostic variables for OS and RFP. In our analysis, we
pooled local recurrences and locoregional recurrences while theTable 3
Multivariate analysis of all VSCC patients (n = 413).
Overall survival
Factor HR (95%CI)




HPVneg/p53wt VSCC 1.56 (0.71–3.40)
HPVneg/p53mut VSCC 1.79 (0.91–3.51)
FIGO stageb I/II 1.0
III/IIIA/IIIB 2.35 (1.46–3.78)
IIIC 4.56 (2.52–8.24)









Positive margin No 1.0
Yes 1.35 (0.85–2.15)
Treatment Surgery 1.0
Surgery & (chemo)radiotherapy 0.75 (0.47–1.20)
HPV = human papillomavirus, HPVpos VSCC = HPV-positive vulvar carcinoma, HPVneg VSC
HPVneg/p53mut VSCC = HPV-negative and p53 mutant VSCC, HR = hazard ratio, LVSI = lym
with locoregional, and were therefore not included in the multivariate analysis. Significant p-v
a Global deviance test without individual parameters.
b We combined the FIGO stages for the analysis into three categories: 1) FIGO stage I and II,
c One patient unknown, excluded from analysis.
654development of local recurrent disease does not necessarily impact
overall survival. Another explanation for the discrepancy between RFP
and OS is that some local recurrences may not be true recurrences but
second primary tumors that may not be equally distributed among the
molecular subtypes. Despite the fact that 101 of 275 HPVneg/p53mutRelative survival Recurrence-free period
p-value RER (95%CI) p-value HR (95%CI) p-value
1.0 1.0
<0.001 1.75 (1.07–2.85) 0.02 1.67 (1.17–2.40) 0.005
0.23a 0.49a 0.0002a
1.0 1.0
0.27 1.47 (0.52–4.15) 0.46 1.37 (0.61–3.08) 0.44
0.09 1.67 (0.72–3.90) 0.23 3.04 (1.59–5.81) 0.001
1.0 1.0
<0.001 3.19 (1.62–6.20) 0.001 0.72 (0.42–1.23) 0.24
<0.001 7.28 (3.34–15.88) <0.001 0.91 (0.44–1.86) 0.80
1.0 1.0
0.03 2.16 (1.02–4.55) 0.04 0.93 (0.60–1.43) 0.75
<0.001 3.94 (1.79–8.69) 0.001 1.07 (0.61–1.87) 0.81
0.74 1.79 (0.13–25.24) 0.67 1.64 (0.39–6.89) 0.50
1.0 1.0
0.95 1.10 (0.56–2.17) 0.79 1.37 (0.90–2.10) 0.14
1.0
0.34 1.09 (0.63–1.89) 0.77
0.97 0.85 (0.30–2.44) 0.75
1.0
0.19 1.49 (0.83–2.68) 0.18
1.0 1.0
0.23 0.66 (0.36–1.23) 0.19 1.48 (0.84–2.59) 0.17
C = HPV-negative VSCC, HPVneg/p53wt VSCC = HPV-negative and p53 wildtype VSCC,
phovascular space invasion, RER = relative excess risk. Only 29 patients were diagnosed
alues are shown in bold.
2) III, IIIA, IIIB, and 3) IIIC due to limitations by sample size.
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the highest risk of recurrence and death. This strongly suggests that
(neo)adjuvant treatment and/or alternative approaches for extended
surgery should be explored in patients with HPVneg/p53mut VSCC.
Presurgical assessment of molecular subtype on biopsies using p16-
and p53-IHC has been shown to be feasible, and therefore may be used
to direct future (surgical) trials [22,33]. HPVneg/p53mut VSCC might
also benefit from a more intensified follow-up schedule and self-
examination in order to detect suspicious lesions earlier [34]. Interest-
ingly, womenwith HPVneg/p53wt VSCC showedmore indolent disease
compared to those with HPVneg/p53mut VSCC, as reflected by better
survival and longer RFP. AlthoughHPVneg/p53wt VSCChad similar clin-
ical characteristics compared to the HPVneg/p53mut VSCC HPVneg/
p53wt VSCC presented with less advanced stage of disease and had
lower risk for recurrent disease. It may be that other oncogenic path-
ways are involved in HPVneg/p53wt VSCC [9], and therefore these tu-
mors may benefit from other targeted therapies.
Patients with HPVpos VSCC had the most favorable clinical out-
comes, as observed across several studies including our own [9,10,18].
Among the 75 HPVpos VSCC in this cohort, fifteen (20%) received adju-
vant (chemo)radiotherapy which is to be expected given the fact the
21% of women in this group had FIGO stage III disease. At present, the
cause for the improved survival for HPVpos VSCC [9,10,18] is unknown,
and may be attributable to the combined effects of therapy and/or less
aggressive biological behavior. It has been shown that HPVpos VSCC
are more sensitive to radiotherapy [35–37] and, as has been suggested
recently, have a more favorable immune infiltrate [38] that may be fur-
ther stimulated by treatment(s). In our study, no data were available on
the adjuvant radiation in terms of the dose and fields that were used.
Therefore, no conclusions could be drawn on the association between
local recurrence risk and radiosensitivity of HPVpos VSCC. The prognos-
tic value of these variables in relation tomolecular subtype, needs to be
validated in a larger cohort including patients with locally advanced or
metastastic disease. Given the suggested higher radiosensitivity in
HPVpos VSCC [35–37], the prognostic relevance of molecular subtypes
in locally advancedVSCCmayeven bemore pronounced than presented
in the current cohort.
The excellent prognosis for HPVpos VSCC might be independent of
treatment. The patients should even after radical surgery sometimes
followed by (chemo)radiotherapy with no survival benefit. HPVpos
OPSCC receive de-intensified adjuvant treatment compared to the
HPV-negative counterpart [39]. In addition, clinical trials in HPVpos
OPSCC are focused on the use of HPV vaccination and checkpoint inhibi-
tion [40], because these tumors seem to have more benefit from (neo)
adjuvant immunotherapy than HPVneg OPSCC [41]. Whether these
treatment strategies may also be applicable to HPVpos/p53wt VSCC
should to be explored given the good clinical outcome in this group.
The use of p16- and p53-IHC as easily accessible, inexpensive and ac-
curate surrogate markers for HPV status and TP53mutational status re-
spectively, has also been shown by others [19,20,22]. Molecular
classification using these assays was successful for 413/420 (98%) of
VSCCs evaluated, stressing the clinical applicability of this approach.
Only one out of 413 VSCC (0.2%) showed a double positive result, as it
was HPV positive (type 18) and showed a mutant p53 immunostaining
pattern (strong diffuse nuclear overexpression). We classified this case
as HPVpos VSCC based on a predefined flowchart. Given the apparent
rarity of this scenario of double positivity larger clinically annotated co-
horts will be required to inform correct assignment. The patient was di-
agnosed with FIGO stage IIIA and no adjacent precursor lesions was
identified. Treatment consisted of awide local excision and adjuvant ra-
diotherapy, after which the patient did not develop any recurrent dis-
ease and survived 11 years until the accrual time of the study. Our
current interpretation is that the TP53 mutation may have been ac-
quired during tumor progression of this particular HPVpos VSCC tumor.
The current study included patients with primary VSCC who were
surgically treated with curative intent, irrespective of adjuvant655treatment given. This resulted in a large but clinically heterogeneous
retrospective study cohort. Therefore, we cannot make any definitive
conclusions with respect to the putative effect of adjuvant treatment
in the different VSCC subtypes. Molecular analysis of a study cohort
from a prospective clinical trial, such as the GROINSS-V studies [42],
would be of interest in exploring the effects of adjuvant radiotherapy
given after sentinel node (SN) biopsy.
Although we were able to include a high number of cases for this
rare cancer type, we were not able to reliably obtain other influencing
factors (e.g., comorbidity, smoking). Due to the retrospective character
of the study, data for the included variables were not complete in all in-
dividuals. Other clinicopathological variables associated with outcomes
[10] should not be neglected. The combination of clinicopathological,
immunological and molecular parameters may be an improvement
upon either system alone, but this needs to be evaluated in future
studies.
In conclusion, we have demonstrated clinicopathological, molecular
and survival differences within VSCC. In addition, we have shown that
molecular classification based on two IHCs is easy and applicable to
FFPE tumor tissue, and results in the identification of three distinct
prognostic VSCC subtypes. The associationwasmaintained after correc-
tion for other prognostic clinicopathological parameters. Our work sug-
gests that molecular classification of VSCC may improve risk prediction
and aid in decisions regarding adjuvant therapies.Wewould like to em-
phasize that a subgroup of HPVneg VSCCwith a better prognosis can be
easily identified by p53-IHC. We postulate that the molecular analyses
performed for this large VSCC cohort, could be easily implemented at
most medical centers since the assays are already in clinical use. Pro-
spective validation of our findings in an independent cohort and further
assessment of treatment efficacy within specific molecular subgroups
will be an important first step to personalized medicine and improved
outcomes for women with VSCC.
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ygyno.2020.09.024.
Ethics approval and consent to participate
The study was conducted in accordance with the Declaration of Hel-
sinki and approved by the local medical ethical committee of the Leiden
University Medical Centre (B16.024) and in agreement with the Dutch
law. Thematerials were used according to theDutch Federation ofMed-
ical Research Association guidelines.
Authors' contribution
KEK: methodology, data curation, formal analysis, writing original
draft.
EB: methodology, data curation, formal analysis, review & editing.
HCvD: data curation, review & editing.
PJdVvS: data curation, review & editing.
PCEG: data curation, review & editing.
CLC: review & editing.
KA: data curation, review & editing.
LSN: data curation, review & editing.
SHvdB: conceptualization, funding acquisition,writing original draft,
supervision.
TB: data curation, conceptualization, funding acquisition, writing
original draft, supervision.
MvP: conceptualization, methodology, funding acquisition, writing
original draft, supervision.
All authors read and approved the final manuscript.
K.E. Kortekaas, E. Bastiaannet, H.C. van Doorn et al. Gynecologic Oncology 159 (2020) 649–656Declaration of Competing Interest
None.
Acknowledgements
We would like to thank Enno Dreef, Natalja ter Haar and Isabelle
Gordijn for their technical support, and Heleen Rogaar for her help with
collecting the clinical data of the cohort.
Funding
KEK was financially supported by a grant from the Dutch Cancer So-
ciety (2016-10168, to MIEvP, TB, and SHvdB).
References
[1] M.S. Schuurman, et al., Trends in incidence and survival of Dutch women with vul-
var squamous cell carcinoma, Eur. J. Cancer 49 (18) (2013) 3872–3880.
[2] P.L. Judson, et al., Trends in the incidence of invasive and in situ vulvar carcinoma,
Obstet. Gynecol. 107 (5) (2006) 1018–1022.
[3] L.J. Eva, et al., Trends in HPV-dependent and HPV-independent vulvar cancers: the
changing face of vulvar squamous cell carcinoma, Gynecol. Oncol. 157 (2) (2020)
450–455, https://doi.org/10.1016/j.ygyno.2020.01.029.
[4] A. Gadducci, et al., Old and new perspectives in themanagement of high-risk, locally
advanced or recurrent, and metastatic vulvar cancer, Crit. Rev. Oncol. Hematol. 60
(3) (2006) 227–241.
[5] N.F. Hacker, Revised FIGO staging for carcinoma of the vulva, Int. J. Gynaecol. Obstet.
105 (2) (2009) 105–106.
[6] M.H.M. Oonk, et al., European Society of Gynaecological Oncology Guidelines for the
management of patients with vulvar Cancer, Int. J. Gynecol. Cancer 27 (4) (2017)
832–837.
[7] L.Woelber, et al., Prognostic role of lymph nodemetastases in vulvar cancer and im-
plications for adjuvant treatment, Int. J. Gynecol. Cancer 22 (3) (2012) 503–508.
[8] K.N. Gaarenstroom, et al., Postoperative complications after vulvectomy and
inguinofemoral lymphadenectomy using separate groin incisions, Int. J. Gynecol.
Cancer 13 (4) (2003) 522–527.
[9] L.S. Nooij, et al., Genomic characterization of vulvar (pre)cancers identifies distinct
molecular subtypes with prognostic significance, Clin. Cancer Res. 23 (22) (2017)
6781–6789.
[10] F. Hinten, et al., Vulvar cancer: two pathwayswith different localization and progno-
sis, Gynecol. Oncol. 149 (2) (2018) 310–317.
[11] I.A. van der Avoort, et al., Vulvar squamous cell carcinoma is a multifactorial disease
following two separate and independent pathways, Int. J. Gynecol. Pathol. 25 (1)
(2006) 22–29.
[12] M.D. Trietsch, et al., Genetic and epigenetic changes in vulvar squamous cell carci-
noma and its precursor lesions: a review of the current literature, Gynecol. Oncol.
136 (1) (2015) 143–157.
[13] M. Olivier, M. Hollstein, P. Hainaut, TP53 mutations in human cancers: origins, con-
sequences, and clinical use, Cold Spring Harb. Perspect. Biol. 2 (1) (2010) a001008.
[14] G. Lindell, et al., Presence of human papillomavirus (HPV) in vulvar squamous cell
carcinoma (VSCC) and sentinel node, Gynecol. Oncol. 117 (2) (2010) 312–316.
[15] G.L. Larsson, et al., Human papillomavirus (HPV) and HPV 16-variant distribution in
vulvar squamous cell carcinoma in Sweden, Int. J. Gynecol. Cancer 22 (8) (2012)
1413–1419.
[16] H.P. van de Nieuwenhof, et al., The etiologic role of HPV in vulvar squamous cell car-
cinoma fine tuned, Cancer Epidemiol. Biomark. Prev. 18 (7) (2009) 2061–2067.
[17] N.F. Hacker, P.J. Eifel, J. van der Velden, Cancer of the vulva, Int. J. Gynaecol. Obstet.
119 (Suppl. 2) (2012) S90–S96.
[18] J.N. McAlpine, et al., Human papillomavirus (HPV)-independent vulvar squamous
cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective
cohort study, Histopathology 71 (2) (2017) 238–246.656[19] K.E. Kortekaas, et al., Performance of the pattern based interpretation of p53 immu-
nohistochemistry as a surrogate for TP53 mutations in vulvar squamous cell carci-
noma, Histopathology 77 (1) (2020) 92–99.
[20] B. Tessier-Cloutier, et al., Major p53 immunohistochemical patterns in in-situ and
invasive squamous cell carcinomas of the vulva and correlation with TP53 mutation
status, Mod. Pathol. 33 (8) (2020) 1595–1605, https://doi.org/10.1038/s41379-020-
0524-1.
[21] P. de Graeff, et al., Modest effect of p53, EGFR and HER-2/neu on prognosis in epithe-
lial ovarian cancer: a meta-analysis, Br. J. Cancer 101 (1) (2009) 149–159.
[22] S. de Sanjose, et al., Worldwide human papillomavirus genotype attribution in over
2000 cases of intraepithelial and invasive lesions of the vulva, Eur. J. Cancer 49 (16)
(2013) 3450–3461.
[23] T.M. Darragh, et al., The lower Anogenital squamous terminology standardization
project for HPV-associated lesions: background and consensus recommendations
from the College of American Pathologists and the American Society for Colposcopy
and Cervical Pathology, Int. J. Gynecol. Pathol. 32 (1) (2013) 76–115.
[24] J.H. Rasmussen, et al., Risk profiling based on p16 and HPV DNA more accurately
predicts location of disease relapse in patients with oropharyngeal squamous cell
carcinoma, Ann. Oncol. 30 (4) (2019) 629–636.
[25] P.C. Lambert, et al., Estimating the crude probability of death due to cancer and
other causes using relative survival models, Stat. Med. 29 (7–8) (2010) 885–895.
[26] D. Sarfati, T. Blakely, N. Pearce, Measuring cancer survival in populations: relative
survival vs cancer-specific survival, Int. J. Epidemiol. 39 (2) (2010) 598–610.
[27] K. Seppa, T. Hakulinen, A. Pokhrel, Choosing the net survival method for cancer sur-
vival estimation, Eur. J. Cancer 51 (9) (2015) 1123–1129.
[28] W.J. Louwman, et al., Clinical epidemiology of breast cancer in the elderly, Eur. J.
Cancer 43 (15) (2007) 2242–2252.
[29] K. Gaarenstroom, et al., Postoperative complications after vulvectomy and
inguinofemoral lymphadenectomy using separate groin incisions, 13(4), 2003
522–527.
[30] J. Coulter, N. Gleeson, Local and regional recurrence of vulval cancer: management
dilemmas, Best Pract Res Clin Obstet Gynaecol 17 (4) (2003) 663–681.
[31] L.J. Rogers, M.A. Cuello, Cancer of the vulva, Int. J. Gynaecol. Obstet. 143 (Suppl. 2)
(2018) 4–13.
[32] M.P. Burger, et al., The importance of the groin node status for the survival of T1 and
T2 vulval carcinoma patients, Gynecol. Oncol. 57 (3) (1995) 327–334.
[33] Singh, N., et al., p53 immunohistochemistry is an accurate surrogate for TP53 muta-
tional analysis in endometrial carcinoma biopsies. J. Pathol., (in press).
[34] M.H. Oonk, et al., The value of routine follow-up in patients treated for carcinoma of
the vulva, Cancer 98 (12) (2003) 2624–2629.
[35] L. Proctor, et al., Association of human papilloma virus status and response to radio-
therapy in vulvar squamous cell carcinoma, Int. J. Gynecol. Cancer 30 (1) (2020)
100–106.
[36] M.J. Dohopolski, et al., The prognostic significance of p16 status in patients with vul-
var Cancer treated with Vulvectomy and adjuvant radiation, Int. J. Radiat. Oncol.
Biol. Phys. 103 (1) (2019) 152–160.
[37] Z.D. Horne, et al., Human papillomavirus infection mediates response and outcome
of vulvar squamous cell carcinomas treated with radiation therapy, Gynecol. Oncol.
151 (1) (2018) 96–101.
[38] K.E. Kortekaas, et al., High numbers of activated helper T cells are associated with
better clinical outcome in early stage vulvar cancer, irrespective of HPV or p53 sta-
tus, J Immunother Cancer 7 (1) (2019) 236.
[39] M. Amin, S. Edge, F. Greene, AJCC Cancer Staging Manual 8th Edition, Springer, New
York, 2017.
[40] E. Massarelli, et al., Combining immune checkpoint blockade and tumor-specific
vaccine for patients with incurable human papillomavirus 16-related Cancer: a
phase 2 clinical trial, JAMA Oncol 5 (1) (2019) 67–73.
[41] C. Pan, N. Issaeva, W.G. Yarbrough, HPV-driven oropharyngeal cancer: current
knowledge of molecular biology and mechanisms of carcinogenesis, Cancers Head
Neck 3 (2018) 12.
[42] M.H. Oonk, et al., Size of sentinel-node metastasis and chances of non-sentinel-node
involvement and survival in early stage vulvar cancer: results from GROINSS-V, a
multicentre observational study, Lancet Oncol. 11 (7) (2010) 646–652.
